APPLICANT FACSANLE OF FORM PTO-THE			Sneet 1 of 6
REV7-60	U.S. DEPARTMENT OF COMMERCE	ATTY OOCIGET NO	SERIAL NO.
	PATENT AND TRADEMARK OFFICE	BBI-6077CP	09/777,554
LIST OF PUBLICATIONS CITE	D BY APPLICANT	APPLICABLY	
(Use several sheets if r	necessary)	Cusack, K. P. et al.	
		FILING DATE	GROUP
		February 8, 2001	1626

U.S. PATENT DOCUMENTS

EXAMPLES JATUA		DOCUMENT NUMBER	DATE	. ; MARE	CLASS	SUBCLASS	FILING DATE
RS	A1	4,966,849	10/90	Vailee et al.	435	199	IF APPROPRIATE
RS	AZ	5,217,999	06/93	Levitzki et al.	514	613	
RS	A3	5,302,606	04/94	Spada et al.	514	357	
RS	A4	5,330,992	07/94	Eissenstat et al.	514	312	

FOREIGN PATENT DOCUMENTS

			COCUALENT NUMBER	DATE	Countrie	CLASS	4/8CLASS	TRAKE	ATION
 	RS	A5	WO 91/15495 A1	10/91	PCT			Yes	NO.
Π	-	A6	WO 92/20642 A1	11/92	PCT		 		
П		A7	WO 92/21660 A1	12/92	PCT				
П		A8	WO 94/03427 A1	02/94	PCT				
		A9	WO 94/10202 A1	05/94	PCT				┼
		A10	WO 94/14808 A1	07/94	РСТ				├
		A11	EP 566 226 B1	11/95	EPO				1
		A12	WO 97/22596 A1	06/97	PCT				-
		A13	WO 97/34876 A1	09/97	PCT	 			-
		A14	WO97/40830 A1	11/97	PCT				├
	Γ	A15	WO 97/40831 A1	11/97	PCT				
1	7	A18	WO 97/42187 A1	11/97	PCT				
F	RS	A17	WO 98/07832 A1	02/98	PCT				├

OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)

'EXA	MINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				
Exam		Date Considered /Rei Tsang Shiao/ (05/15/2006)				
RS	A22	Badger et al., "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function," The Journal of Pharmacology and Experimental Therapeutics, 279:1453-1461 (1996)				
	A21	Armstrong, "Treatment of opportunistic fungal infections," Clinical Infectious Diseases, 16:1-7. (1993)				
\perp	A20	Aplin et al., "In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta," Journal of Neurochemistry, 67:699-707 (1996)				
	A19	Achen et al, "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flk4)," PNAS USA 95(2): 548-553 (1998)				
RS	A18	Expert Opin. Ther. Pat. 8(4): 475-478 (1998)				

APPLICANT FACSHILE OF FORM PTO 1449			St. Joff
	COMMERCE	ATTY DOCKET NO	BERIAL NO.
REV 1-50	PATENT AND TRADEMARK OFFICE	BBI-6077CP	09/777,554
LIST OF PUBLICATIONS CITED	BY APPLICANT	APPLICANT	
(Use several sheets if ne		Cusack, K. P. et al.	
		FILING DATE	1626
		February 8, 2001	1020

OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1 64 1	OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)
RS	81	Baeuerle et et., "Function and activation of NF-kappa B in the immune system," Annual Review of Immunology, 12:141-179 (1994)
	B2	Beg et al., "An essential role for NF-kappaB in preventing TNF-alpha-induced cell death," Science, 274:782-784 (1996)
	ВЗ	Bolen, "Nonreceptor tyrosine protein kinases," Oncogene 8:2025-2031 (1993)
	B4	Borthwick et al., "Inhibition of glycogen synthase kinase-3 by insulin in cultured human skeletal muscle myoblasts," Biochemical & Biophysical Research Communications, 210:738-745 (1995)
	85	Critical Reviews in Oncogenesis, 3:401-406 (1992)
	B6	Brown et al., Regulation of Angiogenesis (ed. L.D. Goldberg and E.M. Rosen), 233-269 (1997)
	B7	Buchdunger et el., "Selective Inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class," PNAS USA 92:2258-2262 (1995)
	88	Courtneidge, "Protein tyrosine kinases, with emphasis on the Src family," Seminars in Cancer Biology, 5:236-246 (1994)
	89	Cowburn, "Peptide recognition by PTB and PDZ domains," Curr. Opin. Struct. Biol, 7(6):835-838 (1997)
	B10	De Vries et al. "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor," Science 255:989-991 (1992)
	B11	Draetta, "Cdc2 activation: The interplay of cyclin binding and Thr161 phosphorylation," <i>Trends in Cell Biology</i> , 3:287-289 (1993)
Ш	B12	Ducommun et al., "cdc2 phosphorylation is required for its interaction with cyclin," EMBO Journa 10:3311-3319 (1991)
	813	Fantl et al., "Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways," Cell 69:413-423 (1992)
	B14	Ferrara et al. "The vascular endothelial growth factor family of polypeptides," J. Cell. Biochem. 47:211-218 (1991)
	B15	Ferrara et al., "Vascular endothelial growth factor. Basic biology and clinical implications," in Regulation of Angiogenesis (ed. L. D. Goldberg and E.M. Rosen), 209-232 (1997)
	B16	Ferrara et al., "The biology of vascular endothellal growth factor," Endocrine Reviews 18(1): 4-28 (1997)
	817	Gautier et al., "Dephosphorylation and activation of Xenopus p34cdc2 protein kinase during the cell cycle," Nature 339:626-629 (1989)
	B18	Gilbert, "Horizontal integration and cortical dynamics," Neuron 9:1-13 (1992)
RS	B19	Girard et al., "Cyclin A is required for the onset of DNA replication in mammalian fibroblasts," Ce 67:1169-1179 (1991)
xami	iner	/Rei Tsang Shiao/ (05/15/2006)
EXA	MINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applica

r	APPLICANT FACEWILE OF FORM PTO-1449			Sheet 3 of 6	
ı		U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERIAL NO.	
ı	REV 7-60	PATENT AND TRADENARK OFFICE	BBI-6077CP	09/777,554	
ı	LIST OF PUBLICATIONS CI	TED BY APPLICANT	APPUCATE		
ı	(Use several sheets		Cusack, K. P. et al.		
ı		•	FILMO DATE	GROUP 1626	
L		· · · · · · · · · · · · · · · · · · ·	February 8, 2001		

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

		OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)
RS	**]	Gould et al., *Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry
	2	into mitosis, Nature, 342:39-45 (1989)
$\perp \! \! \! \! \! \! \! \perp$		He et al., "The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines," Journal of Virology, 71:405–411 (1997)
Ш	3	Hosoi et al., "Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract," Journal of Biochemistry (Tokyo), 117;741-749 (1995)
C	*	Hunter et al., "Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age," Cell, 79:573-58: (1994)
C	5	Jakeman et al., "Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis," Endocrinology 133: 848-859 (1993)
	6	Jellinek, et al., "Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor," Biochemistry 33:10450-56 (1994)
C		Kendall et al., "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," Proc. Natl. Acad. Sci 90:10705-09 (1994)
°		Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature 362:841-844 (1993)
C		Kinsella, et al. "Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, Matrigel," Exp. Cell Res. 199:58-62 (1992)
	10	Klagsburn et al., "Vascular endothelial growth factor and its receptors," Cytokine & Growth Factor Reviews 7: 259-270 (1996)
	15	Koch et al., "SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins," Science 252:668-678 (1991)
	12	Kohn et al., "Cell cycle control and cancer chemotherapy," Journal of Cellular Biochemistry, 54:440-452 (1994)
\coprod	13	Kolch et al., "Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis," Breast Cancer Research and Treatment 36: 139-155 (1995)
	14	Korpelainen et al., "Signaling angiogenesis and lymphanglogenesis," Curr. Opin. Cell Biol., 10:159-164 (1998)
C	15	Krek et al., 'Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLe cells: evidence for a double block to p34cdc2 kinase activation in vertebrates," EMBO Journal, 10:3331-3341 (1991)
C		Lees, "Cyclin dependent kinase regulation," Current Opinion in Cell Biology, 7:773-780 (1995)
	17	Lymboussaki et al, "Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors," Am. J. Pathol. 153(2): 395-403 (1998)
C		Maglione et al. "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14." Oncogene 8:925-31 (1993)
	19	Mariani, et al., "inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," Proc Am. Assoc. Cancer Res. 35:2268 (1994)
X	20	Matsushime et al., "D-type cyclin-dependent kinase activity in mammallan cells," Molecular & Cellular Biology, 14:2066-2076 (1994)
xamine	er	Date Considered /Rei Tsang Sh ao/ (05/15/2006)
EXAMI	NER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applica

APPLICANT FACSINGS OF FORM PTO-1449			Shan = of 8
	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERVAL NO.
REV 7-80	PATENT AND TRADEMARK OFFICE	BBI-8077CP	09/777,554
LIST OF PUBLICATIONS CITED	J BY APPLICANT	APPLICANT	
(Use several sheets if no	ecessary)	Cusack, K. P. et al.	
		FROM DAYS	1626
		February 6, 2001	1020

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) Matthews et al., 'A receptor tyrosine kinase cDNA isolated from a population of enriched primitive RS hematopoietic cells and exhibiting close genetic linkage to c-kit," PNAS USA, 88:9026-30 (1991) D2 Meyer et al, "A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Fit-1) receptor tyrosine kinases," EMBO J. 18(2):363-374 (1999) Migdal et al, "Neuropilin-1 is a placenta growth factor-2 receptor," J. Biol. Chem. 273 (35): 22272-22278 (1998) Millauer et al., "High affinity VEGF binding and developmental expression suggest Flk-1 as a **D4** major regulator of vasculogenesis and angiogenesis," Cell 72:835-846 (1993) 05 Murray et al., "Cyclin synthesis drives the early embryonic cell cycle," Nature, 339:275-280 (1989) DA Mustonen et al., "Endothelial receptor tyrosine kinases involved in angiogenesis," J. Cell Biol. 129:895-898 (1995) 07 Myers et al., "The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)quinazolines; inhibitors of p56th and EGF-R tyrosine kinase activity," Bioorg. Med. Chem. Lett. 7:417-420 (1997) Myers et al., "The synthesis and sar of new 4-(N-alkyl-N-phenyl)amino-6,7dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)amino-pyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity." Bioorganic & Medicinal Chemistry Letters, 7:421-424 (1997) DS Oelrichs et al, "NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo," Oncogene 8(1):11-15 (1993) D10 Ogawa et al, "A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF) preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without hepaninbinding domain, J. Biol. Chem. 273(47): 31273-31282 (1998) Ohtsubo et el., "Cyclin-dependent regulation of G1 in mammalian fibroblasts," Science, 259:1908-1912 (1993) 012 Osmani et al., "Parallel activation of the NIMA and p34cdc2 cell cycle-regulated protein kinases is required to initiate mitosis in A. nidulans," Cell, 67:283-291 (1991) Osmani et al., "Activation of the nimA protein kinase plays a unique role during mitosis that cannot be bypassed by absence of the bimE checkpoint," EMBO Journal, 10:2669-2679 (1991) D14 Pagano et al., "Cyclin A is required at two points in the human cell cycle," EMBO Journal, 11:961-971 (1992) Park et al., "Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Fit-1 but not to Fik-1/KDR." J. Biol. Chem. 269:25646-54 (1994) 016 Perkins et al., "Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 RS coactivator," Science, 275:523-527 (1997) Examiner Date Considered /Rei Tsang Shiao/ (05/15/2006) **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

A Provincial Property Services			Side 1990	
APPLICANT FACILITIES OF FORM PTO-1446	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SEALL NO	
REV 7-60	PATENT AND TRADEMAN OFFICE	BBI-6077CP	09/777,554	
LIST OF PUBLICATIONS CIT	ED BY APPLICANT	APPUCANT		
(Use several sheets if	necessary)	Cusaçk, K. P. et al.		
	•	FLING DATE	⁵⁰⁰ 1626	
		February 8, 2001	1020	

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

		OTHERS (Including Author, Title, Date, Perlinent Pages, Etc.)
RS	E1	Pines, "Cell proliferation and control," Current Opinion in Cell Biology, 4:144-148 (1992)
	E2	Pines, "Cyclins and cyclin-dependent kinases: take your partners," <i>Trends in Biochemical Sciences</i> , 18:195-197 (1993)
	E3	Powis, "Signalling pathways as targets for anticancer drug development." Pharmacology & Therapeutics, 62:57-95 (1994)
	E4	Quelle et al., "Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts," Genes & Development, 7:1559-1571 (1993)
	E5	Resnitzky et al., "Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system," Molecular & Cellular Biology, 14:1669-1679 (1994)
	E6	Ristimaki et al, "Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C," J. Biol. Chem. 273(14):8413-8418 (1998)
	E7	Rosenblatt et al., "Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A." Proc. Nat Acad. Sc. USA, 89:2824-2828 (1992)
	E8	Schlessinger et al., "Growth factor signaling by receptor tyrosine kinases," Neuron 9:383-391 (1992)
	E9	Shawver et al., "Receptor tyrosine kinases as targets for inhibition of angiogenesis," Drug Discovery Today, 2:50-63 (1997)
	E10	Sherr, "Mammalian G1 cyclins," Cell, 73:1059-1065 (1993)
	E11	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family." Oncogene 5:519-524 (1990)
	E12	Shoelson, "SH2 and PTB domain interactions in tyrosine kinase signal transduction," Curr. Opin. Chem. Biol. 1(2): 227-234 (1997)
T	E13	Solomon et al., "Cyclin activation of p34cdc2," Cell, 63:1013-1024 (1990)
	E14	Solomon et al., "Role of phosphorylation in p34cdc2 activation; identification of an activating kinase," Molecular Biology of the Cell, 3:13-27 (1992)
	E15	Songyang et al., "SH2 domains recognize specific phosphopeptide sequences," Cell 72:767-778 (1993)
	E16	Songyang et al., "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav," Mol. Cell. Biol. 14:2777-2785 (1994)
	E17	Staunton et al., "The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and Rhinovirus," Cell 61:243-254 (1990)
	E18	Stone et al., "Reversible, p16-mediated cell cycle arrest as protection from chemotherapy." Cancer Research, 56:3199-3202 (1996)
$\int_{-\infty}^{\infty}$	E19	Takano, et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase," Mol. Bio. Cell 4:358A (1993)
RS	E20	Tanaka et al., *c-CBL is downstream of c-Src in a signalling pathway necessary for bone resorption,* Nature, 383:528-531 (1996)
Exam	niner	/Rei Tsang Shiao/ (05/15/2006)
'EXA	MINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applican

			Sheet 6 of 6
APPLICANT FACSDOLE OF FORM PTO-1449	U.S. DEPARTMENT OF CONNERCE	ATTY DOCKEY NO	SERVL NO
REV 7-40	PATENT AND TRACEMARK OFFICE	BBI-6077CP	09/777,554
LIST OF PUBLICATIONS CIT		APPUCANT	
(Use several sheets if	necessary)	Cusack, K. P. et al.	
		FILING DATE	5800°1626
<u> </u>		February 8, 2001	

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) Terman et al., "Identification of a new andothelial cell growth factor receptor tyrosine kinase." RS Oncogene 6:1677-83 (1991) Terman et al., "Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor," Biochem. Biophys. Res. Comm. 187:1579-86 (1992) Ullrich et al., "Signal transduction by receptors with tyrosine kinase activity," Cell 61:203-212 F4 Van Antwerp et al., "Suppression of TNF-alpha-induced apoptosis by NF-kappaB," Science. 274:787-789 (1996) F5 Vousden, "Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes," FASEB Journal, 7:872-879 (1993) F6 Walker et al., "Role for cyclin A in the dependence of mitosis on completion of DNA replication," Nature, 354:314-317 (1991) Wang et al., "TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB,* Science, 274:784-787 (1996) F8 Williams, "Factors regulating the expression of vascular permeability/vascular endothelial growth factor by human vascular tissues, Diabetelogia 40: S118-120 (1997) Witzenbichler et al, "Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia," Am. J. Pathol. 153(2):381-394 (1998) Wright, et al., "Inhibition of angiogenesis in vitro and in ovo with an inhibitor of cellular protein kinases, MDL 27032," J. Cellular Phys. 152:448-57 (1992) Yarden et al., "Growth factor receptor tyrosine kinases," Ann. Rev. Biochem. 57:443-478 (1988) F12 Zindy et al., "Cyclin A is required in S phase in normal Pepithelial cells," Biochemical & Biophysical Research Communications, 182:1144-1154 (1992) Olofsson et al., "Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells," PNAS USA 95:11709-11714 (1998) Examiner Date Considered /Rei Tsang Shiao/ (05/15/2006) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			_		
APPL	JCANT	FACSIMILE	OF	FORM	PTO-1449

REV 7-80

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

BBI-6077CP

09/777,554

LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)

Cusack, K. P. et al.

GROUP 626

SERIAL NO.

February 8, 2001

U.S. PATENT DOCUMENTS

B INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
RS	A1	4,966,849	10/90	Vallee et al.	435	199	IF APPROPRIATE
RS	A2	5,217,999	06/93	Levitzki et al.	514	613	
RS	А3	5,302,606	04/94	Spada et al.	514	357	
RS	A4	5,330,992	07/94	Eissenstat et al.	514	312	

FOREIGN PATENT DOCUMENTS

			OCCUMENT NUMBER	DATE	Country	CLASS	SUBCLASS	TRANS	LATION
R	s	A5	WO 91/15495 A1	10/91	PCT	 		YES	NO .
Γ	l	A6 ·	WO 92/20642 A1	11/92	PCT	 		 	┼
		A7	WO 92/21660 A1	12/92	PCT	 			
		A8	WO 94/03427 A1	02/94	PCT	 			
		A9	WO 94/10202 A1	05/94	PCT	-			—
		A10	WO 94/14808 A1	07/94	PCT	 			
		A11	EP 566 226 B1	11/95	EPO				
	·	A12	WO 97/22596 A1	06/97	PCT				
		A13	WO 97/34876 A1	09/97	РСТ				
		A14	WO97/40830 A1	11/97	PCT				
		A15	WO 97/40831 A1	11/97	PCT				
	/	A16	WO 97/42187 A1	11/97	PCT	 			
	RS	A17	WO 98/07832 A1	02/98	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

R	s	A18	Expert Opin. Ther. Pat. 8(4): 475-478 (1998)
		A19	Achen et al, "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flk4)," PNAS USA 95(2): 548-553 (1998)
		A20	Aplin et al., "In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta," Journal of Neurochemistry, 67:699-707 (1996)
		A21	Armstrong, "Treatment of opportunistic fungal infections," Clinical Infectious Diseases, 16:1-7 (1993)
\	RS	A22	Badger et al., "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function," The Journal of Pharmacology and Experimental Therapeutics, 279:1453-1461 (1996)
Ex	amir	ter	/Rei Tsang Shiao/ (05/15/2006)
·E	*EXAMINER:		Initial if reference considered, whether or not citation is in conformance with MPEP 609; Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<u> </u>			Sheet 2 of 6
APPLICANT FACSIMILE OF FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERIAL NO.
REV 7-80	PATENT AND TRADEMARK OFFICE	BBI-6077CP	09/777,554
LIST OF PUBLICATIONS (CITED BY APPLICANT	APPLICANT	
(Use several sheet	s if necessary)	Cusack, K. P. et al.	
20		FILING DATE	GROUP 626

February 8, 2001 OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) Baeuerle et al., "Function and activation of NF-kappa B in the immune system," Annual Review of Immunology, 12:141-179 (1994) Beg et al., "An essential role for NF-kappaB in preventing TNF-alpha-induced cell death," Science, 274:782-784 (1996) ŔЗ Bolen, "Nonreceptor tyrosine protein kinases," Oncogene 8:2025-2031 (1993) R4 Borthwick et al., "Inhibition of glycogen synthase kinase-3 by insulin in cultured human skeletal muscle myoblasts," Biochemical & Biophysical Research Communications, 210:738-745 (1995) **B5** Brickell, "The p60c-src family of protein-tyrosine kinases: structure, regulation, and function." Critical Reviews in Oncogenesis, 3:401-406 (1992) 86 Brown et al., Regulation of Angiogenesis (ed. L.D. Goldberg and E.M. Rosen), 233-269 (1997) **B7** Buchdunger et al., "Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class," PNAS USA, 92:2258-2262 (1995) 88 Courtneidge, "Protein tyrosine kinases, with emphasis on the Src family," Seminars in Cancer Biology, 5:236-246 (1994) Cowburn, "Peptide recognition by PTB and PDZ domains," Curr. Opin. Struct. Biol, 7(6):835-838 89 B10 De Vries et al. "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor," Science 255:989-991 (1992) B11 Draetta, "Cdc2 activation: The interplay of cyclin binding and Thr161 phosphorylation," Trends in Cell Biology, 3:287-289 (1993) **B12** Ducommun et al., "cdc2 phosphorylation is required for its interaction with cyclin," EMBO Journal, 10:3311-3319 (1991) Fantl et al., "Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that **B13** mediate different signaling pathways," Cell 69:413-423 (1992) **B14** Ferrara et al. "The vascular endothelial growth factor family of polypeptides," J. Cell. Biochem. 47:211-218 (1991) B15 Ferrara et al., "Vascular endothelial growth factor. Basic biology and clinical implications," in Regulation of Angiogenesis (ed. L. D. Goldberg and E.M. Rosen), 209-232 (1997) B16 Ferrara et al., "The biology of vascular endothelial growth factor," Endocrine Reviews 18(1): 4-25 Gautier et al., "Dephosphorylation and activation of Xenopus p34cdc2 protein kinase during the cell cycle," Nature 339:626-629 (1989) Gilbert, "Horizontal integration and cortical dynamics," Neuron 9:1-13 (1992) **B18** Girard et al., "Cyclin A is required for the onset of DNA replication in mammalian fibroblasts," Cell, **B19** 67:1169-1179 (1991) Examiner Date Considered /Rei Tsang Shiab/ (05/15/2006)

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

BBI-6077CP 09/777,554

LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)

Cusack, K. P. et al.
FILING DATE
FEBRUARY 8 2001

120	February 8, 2001						
5 5000 FA	OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)						
RS C2	Gould et al., "Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates en into mitosis," Nature, 342:39-45 (1989)						
C2	He et al., "The human cytomegalovirus UL97 protein is a protein kinase that autophosphoryla on serines and threonines," Journal of Virology, 71:405-411 (1997)						
C3	on serines and threonines," Journal of Virology, 71:405-411 (1997)						
C4	Hunter et al., "Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age," Cell, 79:573-(1994)						
C5	Jakeman et al., "Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis," Endocrinology 133: 848-859 (1993)						
. C6	Jellinek, et al., "Inhibition of receptor binding by high-affinity RNA ligands to vascular endothe growth factor," <i>Biochemistry</i> 33:10450-56 (1994)						
C7	Kendall et al., "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," Proc. Natl. Acad. Sci 90:10705-09 (1994)						
C8	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature 362:841-844 (1993)						
C9	Kinsella, et al. "Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, Matrigel," Exp. Cell Res. 199:56-62 (1992)						
C10	Klagsburn et al., "Vascular endothelial growth factor and its receptors," Cytokine & Growth Fa Reviews 7: 259-270 (1996)						
C11	Koch et al., "SH2 and SH3 domains: elements that control interactions of cytoplasmic signalin proteins," Science 252:668-678 (1991)						
C12	Kohn et al., "Cell cycle control and cancer chemotherapy," Journal of Cellular Biochemistry, 54:440-452 (1994)						
C13	Kolch et al., "Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis," Breast Cancer Research and Treatment 36: 139-155 (1995)						
C14	Korpelainen et al., "Signaling angiogenesis and lymphangiogenesis," Curr. Opin. Cell Biol., 10:159-164 (1998)						
C15	Krek et al., 'Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in He cells: evidence for a double block to p34cdc2 kinase activation in vertebrates," EMBO Journal 10:3331-3341 (1991)						
C16	Lees, "Cyclin dependent kinase regulation," Current Opinion in Cell Biology, 7:773-780 (1995)						
C17	Lymboussaki et al, "Expression of the vascular endothelial growth factor C receptor VEGFR-3 lymphatic endothelium of the skin and in vascular tumors," Am. J. Pathol. 153(2): 395-403 (19						
C18	Maglione et al. "Two alternative mRNAs coding for the angiogenic factor, placenta growth fa (PIGF), are transcribed from a single gene of chromosome 14," Oncogene 8:925-31 (1993)						
C19	Mariani, et al., "inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," P Am. Assoc. Cancer Res. 35:2268 (1994)						
RS C20	Matsushime et al., "D-type cyclin-dependent kinase activity in mammalian cells," Molecular & Cellular Biology, 14:2066-2076 (1994)						
Examiner	Date Considered /Rei Tsang Shi ao/ (05/15/2006)						
*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to app						

	ADD ICANY CACCUMIC OF SOME			Sheet 4 of 6
	APPLICANT FACSIMILE OF FORM PTQ-1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERIAL NO.
•	REV 7-80	PATENT AND TRADEMARK OFFICE	BBI-6077CP	09/777,554
	LIST OF PUBLICATIONS CI	TED BY APPLICANT	APPUCANT	
-	(Use several sheets	if necessary)	Cusack, K. P. et al.	
•	40		FILING DATE	GROUP 626

February 6, 2001 OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) Matthews et al., "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive. hematopoietic cells and exhibiting close genetic linkage to c-kit," PNAS USA, 88:9026-30 (1991) Meyer et al, "A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates D2 angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases," EMBO J. 18(2):363-374 (1999) 03 Migdal et al, "Neuropilin-1 is a placenta growth factor-2 receptor," J. Biol. Chem. 273 (35): 22272-22278 (1998) Millauer et al., "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis," Cell 72:835-846 (1993) Murray et al., "Cyclin synthesis drives the early embryonic cell cycle," Nature, 339:275-280 (1989) 05 06 Mustonen et al., "Endothelial receptor tyrosine kinases involved in angiogenesis," J. Cell Biol. 129:895-898 (1995) **D7** Myers et al., "The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)quinazolines: inhibitors of p56th and EGF-R tyrosine kinase activity," Bioorg. Med. Chem. Lett. 7:417-420 (1997) Myers et al., "The synthesis and sar of new 4-(N-alkyl-N-phenyl)amino-6,7dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)amino-pyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity," Bioorganic & Medicinal Chemistry Letters, 7:421-424 (1997) D9 Oelrichs et al, "NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo," Oncogene 8(1):11-15 (1993) Ogawa et al, "A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), D10 preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparinbindir g domain," J. Biol. Chem. 273(47): 31273-31282 (1998) **D11** Ohtsubo et al., "Cyclin-dependent regulation of G1 in mammalian fibroblasts," Science, 259:1908-1912 (1993) D12 Osmani et al., "Parallel activation of the NIMA and p34cdc2 cell cycle-regulated protein kinases is required to initiate mitosis in A. nidulans," Cell, 67:283-291 (1991) D13 Osmani et al., "Activation of the nimA protein kinase plays a unique role during mitosis that cannot be bypassed by absence of the bimE checkpoint, EMBO Journal, 10:2669-2679 (1991) Pagano et al., "Cyclin A is required at two points in the human cell cycle," EMBO Journal, 11:961-D15 Park et al., "Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity. in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR." J. Biol. Chem. 269:25646-54 (1994) D16 Perkins et al., "Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator," Science, 275:523-527 (1997) Examiner Date Considered /Rei Tsang Shiao (05/15/2006)

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GROUP1626

APPLICANT FACSIMILE OF FORM PTO-1449
REV 7-80

EXAMINER:

LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE BBI-6077CP SERIL NO.
09/777,554

APPLICANT

Cusack, K. P. et al.

SIPE

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

February 8, 2001

יי	,,,,	<u>Ş</u>	<u>1</u>	OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)		
	м			Pines, "Cell proliferation and control," Current Opinion in Cell Biology, 4:144-148 (1992)		
	1		E2	Pines, "Cyclins and cyclin-dependent kinases: take your partners," <i>Trends in Biochemical Sciences</i> , 18:195-197 (1993)		
			E3	Powis, "Signalling pathways as targets for anticancer drug development," <i>Pharmacology & Therapeutics</i> , 62:57-95 (1994)		
			E4	Quelle et al., "Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts," Genes & Development, 7:1559-1571 (1993)		
			E5	Resnitzky et al., "Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system," Molecular & Cellular Biology, 14:1669-1679 (1994)		
			E6	Ristimaki et al, "Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C," J. Biol. Chem. 273(14):8413-8418 (1998)		
			E7	Rosenblatt et al., "Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A," Proc. Nat Acad. Sc. USA, 89:2824-2828 (1992)		
			E8	Schlessinger et al., "Growth factor signaling by receptor tyrosine kinases," Neuron 9:383-391 (1992)		
			E9	Shawver et al., "Receptor tyrosine kinases as targets for inhibition of angiogenesis," <i>Drug Discovery Today</i> , 2:50-63 (1997)		
Γ			E10	Sherr, "Mammalian G1 cyclins," Cell, 73:1059-1065 (1993)		
			E11	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family," Oncogene 5:519-524 (1990)		
			E12	Shoelson, "SH2 and PTB domain interactions in tyrosine kinase signal transduction," Curr. Opin. Chem. Biol. 1(2): 227-234 (1997)		
			E13	Solomon et al., "Cyclin activation of p34cdc2," Cell, 63:1013-1024 (1990)		
			E14	Solomon et al., "Role of phosphorylation in p34cdc2 activation: identification of an activating kinase," Molecular Biology of the Cell, 3:13-27 (1992)		
			E15	Songyang et al., "SH2 domains recognize specific phosphopeptide sequences," Cell 72:767-778 (1993)		
			E16	Songyang et al., "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav," Mol. Cell. Biol. 14:2777-2785 (1994)		
			E17	Staunton et al., "The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and Rhinovirus," Cell 61:243-254 (1990)		
	Stone et al., "Reversible, p16-mediated cell cycle arrest as protection from chemotherapy," Cancer Research, 56:3199-3202 (1996)					
			E19	Takano, et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase," Mol. Bio. Cell 4:358A (1993)		
	R	S	E20	Tanaka et al., "c-CBL is downstream of c-Src in a signalling pathway necessary for bone resorption," Nature, 383:528-531 (1996)		
	Exa	ami	iner	Date Considered /Rei Tsang Shiao/ (05/15/2006)		
•						

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

:	h	_	•	٠	•	٥f	0

				Sucer 6 01 9
APPUCANT F	ACSIMILE OF FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERIAL NO.
REV 7-80		PATENT AND TRADEMARK OFFICE	BBI-6077CP	09/777,554
LIST	OF PUBLICATIONS CIT	ED BY APPLICANT	APPLICANT .	
/	(Use several sheets i	f necessary)	Cusack, K. P. et al.	
1 /	78	•	FILING DATE	1626
	WAY 0 5 7006		February 8, 2001	

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) rman et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase," RS Oncogene 6:1677-83 (1991) F2 Terman et al., "Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor," Biochem. Biophys. Res. Comm. 187:1579-86 (1992) F3 Ullrich et al., "Signal transduction by receptors with tyrosine kinase activity," Cell 61:203-212 F4 Van Antwerp et al., "Suppression of TNF-alpha-induced apoptosis by NF-kappaB," Science. 274:787-789 (1996) F5 Vousden, "Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes," FASEB Journal, 7:872-879 (1993) F6 Walker et al., "Role for cyclin A in the dependence of mitosis on completion of DNA replication," Nature, 354:314-317 (1991) F7 Wang et al., "TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB," Science, 274:784-787 (1996) FR Williams, "Factors regulating the expression of vascular permeability/vascular endothelial growth factor by human vascular tissues," Diabetelogia 40: S118-120 (1997) F9 Witzenbichler et al, "Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia," Am. J. Pathol. 153(2):381-394 (1998) F10 Wright, et al., "Inhibition of angiogenesis in vitro and in ovo with an inhibitor of cellular protein kinases, MDL 27032," J. Cellular Phys. 152:448-57 (1992) F11 Yarden et al., "Growth factor receptor tyrosine kinases," Ann. Rev. Biochem. 57:443-478 (1988) Zindy et al., "Cyclin A is required in S phase in normal Pepithelial cells," Biochemical & Biophysical Research Communications, 182:1144-1154 (1992) Olofsson et al., "Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells," PNAS USA 95:11709-11714 (1998) Examiner Date Considered /Rei Tsang Shiao/ (05/15/2006) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through

initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.